Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
18/06/2026 06:03
BRIEF-Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination June 18 (Reuters) - ROCHE HOLDING AG ROPC.S:
FDA ACCEPTS SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR ROCHE’S LUNSUMIO AND POLIVY COMBINATION FOR PEOPLE WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
ROCHE HOLDING AG - FDA DECISION ON LUNSUMIO VELO PLUS POLIVY EXPECTED BY FEBRUARY 9, 2027
Source text: ID:nGNE3wmdwg
Further company coverage: ROPC.S
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza